Novel therapies for pancreatic cancer

To date, pancreatic cancer has proved to be one of the most resistant malig nancies, characterized by early local invasion and distant spread. Therefor e, resection with curative intent is limited to a very small proportion of patients. Even in this select group, long-term survival remains very poor. Although radiotherapy and chemotherapy may provide some palliative benefits , these interventions have had minimal impact on overall survival. Over the past several years, 2'-difluoro-2'-deoxycytidine (gemcitabine) has demonst rated modest activity in advanced disease, and investigations are proceedin g to expand its role in the adjuvant setting, in combination with radiother apy, and in combination with other agents. In addition, several new cytotox ic agents are being tested for efficacy in pancreatic cancer. Although thes e drugs may demonstrate clinically meaningful anti-tumor activity, none of them is expected to dramatically alter the natural history of this disease. However, with the identification of the molecular events involved in pancr eatic carcinogenesis, invasion, and metastasis, new agents with specific mo lecular targets are being developed and tested in the clinic. These targets include matrix metalloproteinases, the K-ras oncoprotein, the tumor suppre ssor p53, HER2, epidermal growth factor receptor, and vascular endothelial growth factor. These molecular approaches provide an exciting opportunity t o improve outcomes for patients with pancreatic cancer.